Dickran Kazandjian, Md

This study is testing whether adding a new drug called linvoseltamab to standard maintenance therapy can help eliminate any remaining multiple myeloma cells in patients' bodies. The research aims to help patients achieve and maintain 'minimal residual disease negative' status, me…